Skip to main content
Explore URMC
menu

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Research Question:
What is the effects and the best dose of ruxolitinib phosphate when given together with paclitaxel and carboplatin, and how well do they work in treating patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer?

Basic Study Information

Purpose:
This phase I/II partially randomized trial studies the side effects and the best dose of ruxolitinib phosphate when given together with paclitaxel and carboplatin, and it will look at how well these drugs work in treating patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ruxolitinib phosphate together with paclitaxel and carboplatin may be a better treatment for epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Location: University of Rochester Medical Center
Study Reference #: CGYO19054

Lead Researcher (Principal Investigator)

Lead Researcher: Richard Moore

Study Contact Information

Study Coordinator: Barbara Kavinsky
Phone: (585) 273-3602
Email: Barbara_Kavinsky@URMC.Rochester.edu

Additional Study Details

Return to Search